John M. Evans - 31 Jan 2022 Form 4/A - Amendment Insider Report for Beam Therapeutics Inc. (BEAM)

Role
CEO, Director
Signature
By: /s/ Christine Bellon, Attorney-in-fact
Issuer symbol
BEAM
Transactions as of
31 Jan 2022
Net transactions value
-$3,238,903
Form type
4/A - Amendment
Filing time
02 Feb 2022, 17:00:17 UTC
Date Of Original Report
07 Jul 2021
Previous filing
08 Oct 2021
Next filing
04 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BEAM Common Stock Gift $0 -12,000 -1.2% $0.000000 968,825 16 Nov 2021 Direct
transaction BEAM Common Stock Sale $51,096 -801 -0.08% $63.79 968,024 31 Jan 2022 Direct F2, F3
transaction BEAM Common Stock Sale $140,029 -2,172 -0.22% $64.47 965,852 31 Jan 2022 Direct F2, F4
transaction BEAM Common Stock Sale $208,062 -3,177 -0.33% $65.49 962,675 31 Jan 2022 Direct F2, F5
transaction BEAM Common Stock Sale $421,727 -6,337 -0.66% $66.55 956,338 31 Jan 2022 Direct F2, F6
transaction BEAM Common Stock Sale $912,800 -13,535 -1.4% $67.44 942,803 31 Jan 2022 Direct F2, F7
transaction BEAM Common Stock Sale $271,101 -3,978 -0.42% $68.15 938,825 31 Jan 2022 Direct F2, F8
transaction BEAM Common Stock Options Exercise $103,000 +100,000 +11% $1.03* 1,038,825 31 Jan 2022 Direct
transaction BEAM Common Stock Sale $19,035 -300 -0.16% $63.45 182,700 31 Jan 2022 By John M. Evans, III 2018 Irrevocable Trust F2, F9
transaction BEAM Common Stock Sale $104,103 -1,615 -0.88% $64.46 181,085 31 Jan 2022 By John M. Evans, III 2018 Irrevocable Trust F2, F10
transaction BEAM Common Stock Sale $124,545 -1,900 -1% $65.55 179,185 31 Jan 2022 By John M. Evans, III 2018 Irrevocable Trust F2, F11
transaction BEAM Common Stock Sale $272,900 -4,105 -2.3% $66.48 175,080 31 Jan 2022 By John M. Evans, III 2018 Irrevocable Trust F2, F12
transaction BEAM Common Stock Sale $634,381 -9,408 -5.4% $67.43 165,672 31 Jan 2022 By John M. Evans, III 2018 Irrevocable Trust F2, F13
transaction BEAM Common Stock Sale $182,124 -2,672 -1.6% $68.16 163,000 31 Jan 2022 By John M. Evans, III 2018 Irrevocable Trust F2, F14
holding BEAM Common Stock 980,825 31 Jan 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BEAM Stock Option (Right to Buy) Options Exercise $0 -100,000 -26% $0.000000 284,345 31 Jan 2022 Common Stock 100,000 $1.03 Direct F15
transaction BEAM Stock Option (Right to Buy) Award $0 +112,500 $0.000000 112,500 31 Jan 2022 Common Stock 112,500 $69.21 Direct F16
holding BEAM Stock Option (Right to Buy) 384,345 31 Jan 2022 Common Stock $1.03 Direct F1, F15
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On each of July 7, 2021 and October 6, 2021, the reporting person filed a Form 4 which inadvertently reported an exercise of stock options in connection with certain sales of common stock. In fact, the reporting person did not exercise any stock options in connection with the sales reported on such Forms 4. Accordingly, the first line of each of Tables 1 and 2 of this Form 4 reflects the corrected number of securities beneficially owned by the reporting person prior to the transactions reported herein.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $63.60 to $63.96, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.21 to $64.50, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.20 to $65.99, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.09 to $66.94, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.00 to $67.99, inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $68.00 to $68.60, inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $63.26 to $63.58, inclusive.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.17 to $64.50, inclusive.
F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.20 to $65.99, inclusive.
F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.00 to $66.94, inclusive.
F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.00 to $67.99, inclusive.
F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $68.00 to $68.60, inclusive.
F15 The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested.
F16 The option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the reporting person's continued service with BEAM through each vesting date.